Company news
Capricor Therapeutics, Inc. news in 2023
Capricor Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis
December 10, 2023
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14
November 6, 2023
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program
October 18, 2023
Capricor Therapeutics Announces Late-Breaking Presentations at 28th Annual Congress of the World Muscle Society
October 9, 2023
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
September 28, 2023
Capricor Therapeutics Announces $23 Million Registered Direct Offering
September 28, 2023
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
September 5, 2023
Capricor Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 6, 2023
Capricor Therapeutics to Present Second Quarter 2023 Financial Results and Recent Corporate Update on August 7
August 1, 2023
Capricor Therapeutics Announces Appointment of Philip J. Gotwals, Ph.D. to its Board of Directors
July 23, 2023
Capricor Therapeutics Announces Appointment of Paul Auwaerter, M.D. to its Board of Directors
July 12, 2023
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
June 29, 2023
Capricor Therapeutics to Present 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
June 12, 2023
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
June 6, 2023
Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
Capricor Therapeutics to Present First Quarter 2023 Financial Results and Recent Corporate Update on May 11
May 3, 2023
Capricor Announces Peer-Reviewed Publication Demonstrating the Therapeutic Potential of Exosome-Based Multivalent Vaccine Developed from its StealthX™ Platform
April 26, 2023
Capricor Therapeutics Presents at 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
March 22, 2023
Capricor Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 14, 2023
Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy in Japan
February 15, 2023
Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
January 24, 2023
Capricor Announces Publication Highlighting New Advances for its Engineered Exosome Platform
January 11, 2023
Calls in 2023
- Capricor Therapeutics (NASDAQ:CAPR) Q3 2023 Earnings Call
Nov 14, 2023
Transcript - Capricor Therapeutics (NASDAQ:CAPR) Q2 2023 Earnings Call
Aug 7, 2023
Transcript - Capricor Therapeutics (NASDAQ:CAPR) Q1 2023 Earnings Call
May 11, 2023
Transcript - Capricor Therapeutics (NASDAQ:CAPR) Q4 2022 Earnings Call
Mar 15, 2023
Transcript